I get you point about getting data/trials etc adding value to the valuation. However, this would result in many possible positive catalysts following the process of filing IND and all the clinical trial phases. There would be numerous opportunities along the way. Plus NGIO needs the money now for all the other trials. GNBT probably can't afford the wait either unless the plan is to continue to dilute us a 20 cents which is really po'ing me.

Still, given Generex's history of extreme delays, the scenario you present is a possibility.